Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes

Trial Profile

A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efpeglenatide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms BALANCE 205
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 11 Jun 2019 Results of an exploratory subgroup analysis assessing effect of Efpeglenatide on body wieght, BMI and waist circumference from baseline to wk 21 vs placebo presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 11 Jun 2019 Results of a sub-analysis assessing efficacy of Efpeglenatide presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
    • 17 Oct 2018 Patients were not recruited from Czech Republic.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top